Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor res (Q38309035)
Jump to navigation
Jump to search
scientific article published on 28 September 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor res |
scientific article published on 28 September 2006 |
Statements
1 reference
Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor res (English)
1 reference
S Loibl
1 reference
A Rody
1 reference
T Karn
1 reference
R Gätje
1 reference
A Ahr
1 reference
C Solbach
1 reference
K Kourtis
1 reference
M Munnes
1 reference
S Kissler
1 reference
E Ruckhäberle
1 reference
U Holtrich
1 reference
G von Minckwitz
1 reference
M Kaufmann
1 reference
28 September 2006
1 reference
1 reference
16
1 reference
1
1 reference
86-93
1 reference
Identifiers
1 reference
1 reference